Using copper-depleting nanotechnology to treat triple-negative breast cancer
Copper-depleting nanotheranostics for treating triple negative breast cancer
This study is exploring a new way to help people with triple-negative breast cancer by using special technology to lower copper levels in the body, which may help slow down cancer growth and spread.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10684918 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating triple-negative breast cancer (TNBC) by targeting copper levels in the body. The study aims to develop a nanotechnology-based platform that can effectively deplete excess copper, which is linked to cancer progression and metastasis. By utilizing this self-reporting nanoplatform, the researchers hope to inhibit tumor growth and spread in patients with TNBC. The methodology involves understanding the biochemical roles of copper in cancer biology and applying innovative nanotechnology to enhance treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who may benefit from novel treatment strategies.
Not a fit: Patients with other subtypes of breast cancer or those who do not have elevated copper levels may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients with triple-negative breast cancer, potentially improving survival rates and treatment efficacy.
How similar studies have performed: While the approach of using copper depletion in cancer treatment is recognized, this specific application of nanotechnology in TNBC is innovative and has not been extensively tested in prior studies.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Rao, Jianghong — Stanford University
- Study coordinator: Rao, Jianghong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.